vs
Side-by-side financial comparison of GLAUKOS Corp (GKOS) and TANDEM DIABETES CARE INC (TNDM). Click either name above to swap in a different company.
TANDEM DIABETES CARE INC is the larger business by last-quarter revenue ($247.2M vs $150.6M, roughly 1.6× GLAUKOS Corp). GLAUKOS Corp runs the higher net margin — 6.2% vs -8.2%, a 14.5% gap on every dollar of revenue. On growth, GLAUKOS Corp posted the faster year-over-year revenue change (41.2% vs 5.5%). Over the past eight quarters, GLAUKOS Corp's revenue compounded faster (25.4% CAGR vs 5.5%).
Glaukos Corp is a medical technology company focused on ophthalmology, developing and commercializing minimally invasive surgical devices, prescription pharmaceuticals and consumer products for glaucoma, corneal diseases and other eye disorders. It operates primarily across North America, Europe and Asia Pacific, serving hospitals, ophthalmology clinics and patients worldwide.
Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
GKOS vs TNDM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $150.6M | $247.2M |
| Net Profit | $9.4M | $-20.4M |
| Gross Margin | 77.9% | 55.3% |
| Operating Margin | 9.0% | 37.6% |
| Net Margin | 6.2% | -8.2% |
| Revenue YoY | 41.2% | 5.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $150.6M | $247.2M | ||
| Q4 25 | $143.1M | $290.4M | ||
| Q3 25 | $133.5M | $249.3M | ||
| Q2 25 | $124.1M | $240.7M | ||
| Q1 25 | $106.7M | $234.4M | ||
| Q4 24 | $105.5M | $282.6M | ||
| Q3 24 | $96.7M | $244.0M | ||
| Q2 24 | $95.7M | $221.9M |
| Q1 26 | $9.4M | $-20.4M | ||
| Q4 25 | $-133.7M | $-589.0K | ||
| Q3 25 | $-16.2M | $-21.2M | ||
| Q2 25 | $-19.7M | $-52.4M | ||
| Q1 25 | $-18.1M | $-130.6M | ||
| Q4 24 | $-33.6M | $755.0K | ||
| Q3 24 | $-21.4M | $-23.3M | ||
| Q2 24 | $-50.5M | $-30.8M |
| Q1 26 | 77.9% | 55.3% | ||
| Q4 25 | -1.1% | 57.7% | ||
| Q3 25 | 78.4% | 53.9% | ||
| Q2 25 | 78.3% | 52.3% | ||
| Q1 25 | 77.2% | 50.5% | ||
| Q4 24 | 72.9% | 55.7% | ||
| Q3 24 | 76.6% | 51.1% | ||
| Q2 24 | 76.4% | 50.8% |
| Q1 26 | 9.0% | 37.6% | ||
| Q4 25 | -97.7% | 2.9% | ||
| Q3 25 | -12.3% | -9.2% | ||
| Q2 25 | -18.3% | -21.5% | ||
| Q1 25 | -19.4% | -51.6% | ||
| Q4 24 | -27.2% | -0.2% | ||
| Q3 24 | -25.5% | -10.7% | ||
| Q2 24 | -31.3% | -13.9% |
| Q1 26 | 6.2% | -8.2% | ||
| Q4 25 | -93.4% | -0.2% | ||
| Q3 25 | -12.2% | -8.5% | ||
| Q2 25 | -15.8% | -21.8% | ||
| Q1 25 | -17.0% | -55.7% | ||
| Q4 24 | -31.8% | 0.3% | ||
| Q3 24 | -22.1% | -9.5% | ||
| Q2 24 | -52.8% | -13.9% |
| Q1 26 | — | $-0.30 | ||
| Q4 25 | $-2.34 | $0.02 | ||
| Q3 25 | $-0.28 | $-0.31 | ||
| Q2 25 | $-0.34 | $-0.78 | ||
| Q1 25 | $-0.32 | $-1.97 | ||
| Q4 24 | $-0.56 | $0.00 | ||
| Q3 24 | $-0.39 | $-0.35 | ||
| Q2 24 | $-1.00 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $276.7M | $570.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $670.9M | $132.4M |
| Total Assets | $893.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $276.7M | $570.3M | ||
| Q4 25 | $90.8M | $292.7M | ||
| Q3 25 | $98.2M | $319.1M | ||
| Q2 25 | $100.8M | $315.4M | ||
| Q1 25 | $114.3M | $368.6M | ||
| Q4 24 | $169.6M | $438.3M | ||
| Q3 24 | $100.1M | $473.3M | ||
| Q2 24 | $68.1M | $452.4M |
| Q1 26 | $670.9M | $132.4M | ||
| Q4 25 | $656.2M | $155.2M | ||
| Q3 25 | $769.5M | $133.0M | ||
| Q2 25 | $765.1M | $133.3M | ||
| Q1 25 | $764.0M | $155.3M | ||
| Q4 24 | $766.9M | $263.1M | ||
| Q3 24 | $668.5M | $237.7M | ||
| Q2 24 | $665.2M | $233.9M |
| Q1 26 | $893.3M | $1.2B | ||
| Q4 25 | $893.5M | $881.1M | ||
| Q3 25 | $999.4M | $874.7M | ||
| Q2 25 | $987.0M | $875.7M | ||
| Q1 25 | $966.2M | $922.1M | ||
| Q4 24 | $974.8M | $967.7M | ||
| Q3 24 | $926.5M | $957.7M | ||
| Q2 24 | $919.7M | $937.5M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
